POLARIS INSIGHTS

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

Key PointsEli Lilly recently announced results from a clinical trial that showed the company may have an even better weight loss treatment in the works.

Read the full account of the story

More from Markets · Back to Polaris Insights

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

More from the Markets desk